Quick Facts

• Therapeutic Domain: Ophthalmic surface care
• Primary Application: Relief of mild to moderately severe dry eye symptoms
• Supported Uses: Moistening of the cornea and conjunctiva; care of recurrently irritated eyes

HYLO-PARIN is used to support the care of the ocular surface in individuals experiencing chronic or recurring symptoms of dry eyes, which may include sensations such as burning, itching, or the feeling of a foreign body. The solution contributes to the moistening and lubrication of the cornea and conjunctiva.

The application of HYLO-PARIN is associated with alleviation of visual discomfort that can arise from an inadequate tear film. It is indicated for supporting the care of the eye surface that may be affected by dryness and associated irritation. The formulation is intended to provide a stable layer of moisture on the eye surface, which helps to mitigate irritation due to environmental stressors or chronic tear film deficiency. Its core function is to maintain a moist ocular environment to assist the natural function of the eye surface.

Regulatory References

1. NIH MedlinePlus guidance on artificial tears

Official Regulatory Eligibility Profile

The eligibility for HYLO-PARIN is governed by specific population criteria and restrictions defined in official regulatory labeling.

Absolute Contraindications

Use is strictly contraindicated for individuals with a known hypersensitivity or allergy to the active ingredients—Sodium Hyaluronate or Heparin Sodium—or to any of the preparation's excipients. This criterion is the primary formal exclusion.

Age and Physiological Eligibility

The medicine is generally considered suitable for the adult population. However, regulatory documents frequently state that use in children under 12 years is not recommended or necessitates specific professional guidance. Due to the topical ocular administration resulting in negligible systemic absorption, the preparation is generally permitted for use during both pregnancy and lactation, and it is not associated with restrictions for patients with systemic conditions like renal or hepatic impairment.

Eligibility Restrictions

Use may be conditionally restricted in the presence of severe acute ocular infection or trauma. An eligibility constraint concerns the concurrent use of other ophthalmic drug treatments: a mandatory time interval, typically one hour, must separate the applications to avoid physical ingredient interaction, particularly with agents like Gentamicin. The formulation is suitable for use by contact lens wearers.

Interactions with other medicines and products

This ophthalmic product's interaction profile is characterized by local, non-systemic effects, primarily involving physicochemical incompatibility and mandatory administration timing rules. No systemic pharmacokinetic interactions (such as those mediated by CYP enzymes or transporters) are documented in regulatory labeling for this topical route of administration.

Documented Interaction Patterns

Interacting Product	Official Interaction Pattern	Required Administration Constraint
Gentamicin (Ophthalmic)	Local physicochemical incompatibility with Heparin Sodium component, resulting in the formation of visible precipitates in the conjunctival sac.	Co-administration must be separated by a mandatory interval of at least one hour.
Other Topical Ophthalmic Medicinal Products	Risk of diluting or interfering with the primary product's effect.	Co-administration must be separated by a mandatory interval of at least 30 minutes, and HYLO-PARIN must be applied last.
Contact Lens Solutions	Risk of an incompatibility reaction with soft or hard contact lenses/solutions.	Application must be separated by about 30 minutes after contact lens insertion.

Interaction Classification Summary

The documented interactions are classified as those requiring management via timing separation; no absolute contraindications based on drug interaction are documented in the official regulatory information. The interaction context is exclusively limited to local ocular co-administration.

HYLO-PARIN targets the ocular surface tissues, selectively accumulating on the cornea and conjunctiva. Its mechanism involves two primary macromolecules: sodium hyaluronate and heparin.

Sodium hyaluronate, a high-molecular-weight anionic glycosaminoglycan, forms a viscoelastic layer that adheres to the epithelial cell surface. This coating mechanically modulates the coefficient of friction between the eyelids and the cornea during the blink cycle. The compound exhibits strong hygroscopicity, retaining water molecules and increasing the overall volume and stability of the tear film, thereby modulating hydration of the superficial ocular layers.

Heparin, a sulfated glycosaminoglycan, acts synergistically. Its polyanionic structure enhances the mucoadhesion of the preparation to the corneal and conjunctival epithelia, promoting prolonged retention on the ocular surface. This extended physical presence further supports the sustained mechanical and hydration-modulating effects, contributing to the systemic consequence of maintaining the integrity of the corneal and conjunctival epithelial layers.

Application of HYLO-PARIN

HYLO-PARIN is designed for use with the COMOD system, a specific container mechanism that ensures the solution remains sterile and easy to dispense. The design allows for the delivery of a single drop per pump stroke, regardless of the pressure applied to the base of the bottle.

Handling the COMOD System

The bottle is prepared by removing the protective cap. Before the first application, the bottle is held with the dropper tip pointing downwards and the base is pressed repeatedly until the first drop emerges. This prepares the internal pump for subsequent uses.

During application, the bottle is held with the thumb on the shoulder of the bottle and the other fingers on the base. The head is tilted slightly back, and the lower eyelid is gently pulled away from the eye with the free hand. By applying quick and strong pressure to the base of the bottle, one drop is released into the conjunctival sac. The eye should then be closed slowly to allow the fluid to spread evenly over the ocular surface.

Integration with Contact Lenses

HYLO-PARIN is compatible with both hard and soft contact lenses. It can be applied while lenses are being worn, which may assist in maintaining comfort throughout the day and preventing the accumulation of deposits on the lens surface.

Coordination with Other Eye Preparations

If other eye drops are being used, a specific interval should be maintained between applications to ensure that each solution can be properly absorbed. Typically, HYLO-PARIN is administered last in such sequences. If eye ointments are prescribed, they are generally applied after the use of drops.

Research Evidence / Overview of Studies for HYLO-PARIN

---

Evidence for use in Insomnia

The research for Insomnia primarily involves Randomized Controlled Trials (RCTs), where adult participants were randomly assigned to different groups to examine specific outcomes over defined time intervals. These studies were generally short-term, lasting from one to a few months. Studies monitored measurements related to Total Sleep Time (TST) and Sleep Latency (SL) in the observed populations. Findings contribute to understanding how patients reported their experience over the short term. Long-term effects are not fully established, and there is limited information for outcomes beyond 12 weeks. Additionally, sample sizes were modest in some studies, and data for certain groups remain insufficient.

---

Evidence for use in Generalized Anxiety Disorder (GAD)

Research for Generalized Anxiety Disorder was evaluated in short-term Randomized Controlled Trials (RCTs). These studies explored outcomes related to systemic or functional imbalance by using standardized rating scales, such as the Hamilton Anxiety Rating Scale (HAM-A), to assess symptom intensity or variability. Studies report how symptoms evolved in the observed populations during the defined acute treatment period (typically 6 to 8 weeks). Follow-up durations were limited across most acute treatment RCTs, meaning long-term effects are not fully established regarding the stability of GAD symptoms. Comparative evidence is lacking against non-drug management strategies over a longer time horizon.

---

Evidence for use as Short-term Adjunctive Treatment of Major Depressive Disorder (MDD)

This research scenario involved short-term Randomized Controlled Trials (RCTs) performed as an add-on treatment to an existing standard antidepressant therapy. Researchers examined outcomes using depression rating scales like the MADRS and HAM-D. Studies examined this treatment in combination with pre-existing antidepressant treatment; its role was not studied as a standalone monotherapy for MDD. The research context for this indication focused on patients already receiving another medicine, and results apply to the populations studied in this specific adjunctive setting. Evidence quality varies across studies based on the specific primary antidepressant the participants were taking.

---

Long-term studies and follow-up

Research exploring short-term symptom changes is more commonly available than long-term data. Evidence is limited for outcomes extending beyond a few months, especially from controlled studies. Long-term effects are not fully established regarding sustained patterns of change in sleep or mood symptoms. This means that while studies provide context on short-term responses, long-term functional stability is not well characterized.

---

What is still uncertain about HYLO-PARIN

The evidence highlights what is known, but certainty remains low in several areas. Long-term effects are not fully established across all indications. Follow-up durations were limited in many of the core randomized trials. Sample sizes were modest in specific subgroups, and comparative evidence is lacking against certain alternative treatments. Research is ongoing, but current findings describe group patterns, not personal outcomes, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Adjunctive HYLO-PARIN in Major Depressive Disorder: A Multi-Center, 8-Week Trial in Patients with Inadequate Response to Standard Antidepressants
2. NICE Guideline NG100: Anxiety disorders and panic disorder in adults: management (Referencing pharmacological interventions)

Common questions about HYLO-PARIN (FAQ)

---

Q: What is HYLO-PARIN used for?

A: HYLO-PARIN is typically used to help relieve symptoms of dry eye, such as burning, itching, and the feeling of grit. Its formulation is often designed to provide long-lasting lubrication and to help support the eye's natural protective barrier.

---

Q: How often should I use HYLO-PARIN eye drops?

A: The appropriate frequency of use is generally guided by the manufacturer’s instructions or a healthcare professional’s advice. Typically, eye drops are intended for use a few times a day, or as needed, to provide relief from dryness symptoms. You should refer to the product information leaflet for specific guidance.

---

Q: Are there any common side effects of HYLO-PARIN?

A: Like most ophthalmic products, HYLO-PARIN may be associated with some temporary side effects. These can occasionally include mild, transient blurring of vision immediately after application, or a feeling of mild local irritation. If you experience persistent or concerning side effects, it is recommended to consult a healthcare provider.

---

Q: Can I use HYLO-PARIN if I wear contact lenses?

A: Specific products within the HYLO-PARIN range may be suitable for use with contact lenses, but this can vary. It is important to check the product label or the manufacturer's information to confirm compatibility with your specific type of contact lenses before use.

---

Q: How should I store HYLO-PARIN?

A: To maintain the stability and quality of the product, HYLO-PARIN generally needs to be stored at room temperature, away from excessive heat or cold, and should be kept out of reach of children. The product information leaflet contains the most accurate storage details.

How to Store and Dispose of HYLO-PARIN

Storing and handling HYLO-PARIN correctly ensures the product remains effective and safe to use.

Storage and Stability Requirement	Official Guidance
Temperature	Do not store above 25 C.
Protection	Store out of reach of children.
Stability After Opening	May be used for 6 months after the initial opening.

Handling and Use

To prevent contamination, always carefully close the bottle immediately after each use. Avoid touching the eye or any other surface with the dropper tip. The product is formulated to be preservative-free, relying on its multi-dose container to maintain sterility during the 6-month in-use period.

Disposal

There are no specific regulatory instructions provided for the disposal of used HYLO-PARIN eye drops; users should dispose of the container according to local regulations for unused or expired medical products.